Roger Song
Stock Analyst at Jefferies
(3.84)
# 668
Out of 5,056 analysts
49
Total ratings
45%
Success rate
13.14%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Roger Song
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GYRE Gyre Therapeutics | Initiates: Buy | $16 | $8.34 | +91.85% | 1 | Oct 10, 2025 | |
| UTHR United Therapeutics | Maintains: Buy | $432 → $564 | $461.54 | +22.20% | 1 | Sep 2, 2025 | |
| BMEA Biomea Fusion | Initiates: Buy | $5 | $1.37 | +264.96% | 1 | Aug 28, 2025 | |
| ATYR aTyr Pharma | Maintains: Buy | $9 → $17 | $0.72 | +2,251.96% | 2 | Aug 22, 2025 | |
| MBX MBX Biosciences | Assumes: Buy | $36 | $24.60 | +46.34% | 1 | Aug 15, 2025 | |
| LVTX LAVA Therapeutics | Downgrades: Hold | $3 → $1.5 | $1.60 | -6.25% | 1 | Aug 5, 2025 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Buy | $45 → $54 | $40.58 | +33.07% | 3 | Jul 29, 2025 | |
| REPL Replimune Group | Maintains: Buy | $31 → $6 | $9.04 | -33.63% | 2 | Jul 22, 2025 | |
| CVAC CureVac | Downgrades: Hold | $7 → $5 | $5.34 | -6.37% | 1 | Jun 13, 2025 | |
| NKTR Nektar Therapeutics | Upgrades: Buy | $15 → $30 | $57.67 | -47.98% | 11 | Apr 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $1.85 | +224.32% | 1 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $4.06 | +72.41% | 1 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $245 | $203.03 | +20.67% | 1 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $6.96 | +273.83% | 1 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $42 → $7 | $8.01 | -12.61% | 2 | Dec 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $28 | $10.68 | +162.17% | 2 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $2 → $7 | $2.41 | +190.46% | 1 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $89 | $86.11 | +3.36% | 1 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $25 | $7.20 | +247.22% | 2 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $41 | $12.17 | +236.89% | 1 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $35.80 | -2.23% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $108 → $129 | $46.10 | +179.83% | 1 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $2.5 → $8 | $4.23 | +89.13% | 3 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $97 | $97.06 | -0.06% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $110 | $40.78 | +169.74% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $35 | $4.23 | +727.42% | 1 | Aug 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $1.47 | +512.24% | 1 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $8.18 | -2.20% | 2 | Dec 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $0.81 | +2,489.72% | 1 | Sep 2, 2020 |
Gyre Therapeutics
Oct 10, 2025
Initiates: Buy
Price Target: $16
Current: $8.34
Upside: +91.85%
United Therapeutics
Sep 2, 2025
Maintains: Buy
Price Target: $432 → $564
Current: $461.54
Upside: +22.20%
Biomea Fusion
Aug 28, 2025
Initiates: Buy
Price Target: $5
Current: $1.37
Upside: +264.96%
aTyr Pharma
Aug 22, 2025
Maintains: Buy
Price Target: $9 → $17
Current: $0.72
Upside: +2,251.96%
MBX Biosciences
Aug 15, 2025
Assumes: Buy
Price Target: $36
Current: $24.60
Upside: +46.34%
LAVA Therapeutics
Aug 5, 2025
Downgrades: Hold
Price Target: $3 → $1.5
Current: $1.60
Upside: -6.25%
Kiniksa Pharmaceuticals International,
Jul 29, 2025
Maintains: Buy
Price Target: $45 → $54
Current: $40.58
Upside: +33.07%
Replimune Group
Jul 22, 2025
Maintains: Buy
Price Target: $31 → $6
Current: $9.04
Upside: -33.63%
CureVac
Jun 13, 2025
Downgrades: Hold
Price Target: $7 → $5
Current: $5.34
Upside: -6.37%
Nektar Therapeutics
Apr 11, 2025
Upgrades: Buy
Price Target: $15 → $30
Current: $57.67
Upside: -47.98%
Apr 1, 2025
Initiates: Buy
Price Target: $6
Current: $1.85
Upside: +224.32%
Mar 14, 2025
Initiates: Buy
Price Target: $7
Current: $4.06
Upside: +72.41%
Mar 5, 2025
Initiates: Buy
Price Target: $245
Current: $203.03
Upside: +20.67%
Feb 25, 2025
Initiates: Buy
Price Target: $26
Current: $6.96
Upside: +273.83%
Dec 9, 2024
Downgrades: Hold
Price Target: $42 → $7
Current: $8.01
Upside: -12.61%
Nov 21, 2024
Maintains: Buy
Price Target: $32 → $28
Current: $10.68
Upside: +162.17%
Nov 19, 2024
Upgrades: Buy
Price Target: $2 → $7
Current: $2.41
Upside: +190.46%
Oct 23, 2024
Initiates: Buy
Price Target: $89
Current: $86.11
Upside: +3.36%
Oct 16, 2024
Maintains: Buy
Price Target: $31 → $25
Current: $7.20
Upside: +247.22%
Oct 11, 2024
Initiates: Buy
Price Target: $41
Current: $12.17
Upside: +236.89%
Oct 8, 2024
Initiates: Buy
Price Target: $35
Current: $35.80
Upside: -2.23%
Sep 3, 2024
Maintains: Buy
Price Target: $108 → $129
Current: $46.10
Upside: +179.83%
May 6, 2024
Upgrades: Buy
Price Target: $2.5 → $8
Current: $4.23
Upside: +89.13%
Apr 17, 2024
Initiates: Buy
Price Target: $97
Current: $97.06
Upside: -0.06%
Mar 7, 2024
Initiates: Buy
Price Target: $110
Current: $40.78
Upside: +169.74%
Aug 31, 2022
Maintains: Buy
Price Target: $30 → $35
Current: $4.23
Upside: +727.42%
Jul 29, 2022
Initiates: Buy
Price Target: $9
Current: $1.47
Upside: +512.24%
Dec 1, 2021
Initiates: Buy
Price Target: $8
Current: $8.18
Upside: -2.20%
Sep 2, 2020
Initiates: Buy
Price Target: $21
Current: $0.81
Upside: +2,489.72%